药物再定位的发展历程与进展

摘要/Abstract

摘要： 安全、有效、质量可控”是新药研发的基本原则。新药研发投入大、风险高、周期长。近年来，世界范围内药物研发面临疾病系统性及如何控制临床风险等理论和技术上新的瓶颈，新药的投入产出比呈明显下降趋势。药物再定位是针对已获批上市或未上市但成分明确、生物活性已知的药物，探寻其潜在的作用机制，扩大其适用范围的过程。与基于新物质新作用机制的原始创新药物研发相比，药物再定位在资金投入、研发周期和风险等方面具有明显优势。本研究结合具体实例，综述药物再定位领域国内外进展情况、相关主要的策略和技术方法，进而对于药物再定位策略的潜在优势领域和我国药物再定位领域的前景及挑战提出思考。

关键词: font-size:medium, ">药物再定位；药效学；新适应证；新药研发

Abstract: "Safety， effectiveness and controllable quality" are the basic principles of new drug research and development， and the research and development of new drug need large ivestment， and have high risk and long cycle. In recent years， drug research and development around the world began to face new theoretical and technical bottlenecks， such as disease systematicness and how to control clinical risks. The input-output ratio of new drugs showed a significant downward trend. Drug repurposing is a process to explore the potential mechanism of action and expand the scope of application of drugs that have been approved for marketing or drugs that have clear ingredients and known biological activities although not yet on the market. Compared with the research and development of original new drug， drug repurposing has obvious advantages in capital investment， development cycle and risk. Combined with specific examples， this paper summarizes the progress， relevant main strategies and technical methods in the field of drug repurposing at home and abroad， and then puts forward some thoughts on the potential advantages of drug repurposing strategy and the prospects and challenges in the field of drug repurposing in China.

Key words: Drug repurposing, Pharmacodynamics, New indications, New drug research and development

中图分类号:

王涛, 尚靖. 药物再定位的发展历程与进展[J]. 中国医药导刊, 2022, 24(4): 325-333.

WANG Tao, SHANG Jing. The Development and Research Progress of Drug Repurposing[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(4): 325-333.

参考文献

[1] 汤仲明，高柳村.美国FDA批准新药十年（2007-2016）纵观分析[J].国际药学研究杂志，2016，43(6):1009-1030.
     [2]Hua Y，Dai X，Xu Y，et al.Drug repositioning:progress and challenges in drug discovery for various diseases[J]. Eur J Med Chem， 2022， 234:114239.
     [3]FDA.New Drugs at FDA: CDER′s New Molecular Entities and New Therapeutic Biological Products[EB/OL].（2022-01-27）[2022-03-30].https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products.
     [4]Polamreddy P，Gattu N.The drug repurposing landscape from 2012 to 2017:evolution， challenges，and possible solutions[J].Drug Discov Today，2019， 24(3):789-795.
     [5]班雅倩，常新义，袁晓龙，等.对我国药品上市后再评价工作的文献分析[J].中国药房，2014，25（9）：859-862.
     [6]邰杨芳，王帅，张芬利，等.国内药物重定位研究的主题及发展脉络分析[J].中国新药杂志，2020，29（22）：2541-2551.
     [7]Nosengo N. Can you teach old drugs new tricks? [J]. Nature， 2016， 534(7607):314-316.
     [8]Arrowhead Publishers.10th Annual Drug Repositioning and Repurposing Conference[EB/OL].[2022-03-30].https://www.drugrepositioningconference.com.
     [9]Zamami Y， Hamano H， Niimura T， et al. Drug-repositioning approaches based on medical and life science databases[J]. Front Pharmacol， 2021， 12:752174.
     [10]张明发.关于成立药物再评价基金组织的建议[J].抗感染药学，2015，12(2):165-168.
     [11]Pushpakom S，Iorio F，Eyers PA，et al.Drug repurposing：progress，challenges and recommendations[J].Nat Rev Drug Discov，2019，18(1):41-58.
     [12]Rapicavoli RV，Alaimo S，Ferro A，et al. Computational methods for drug repurposing[J]. Adv Exp Med Biol，2022，1361:119-141.
     [13]Sadegh S，Skelton J， Anastasi E，et al.Network medicine for disease module identification and drug repurposing with the NeDRex platform[J]. Nat Commun，2021，12(1):6848.
     [14]Zhou LL，Cai MX，Shang J，et al.The different roles of 5-HT1A/2A receptors in fluoxetine ameliorated pigmentation of C57BL/6 mouse skin in response to stress[J].J DermatolSci，2018， 92(3):222-229.
     [15]Liu L，Fu MS，Shang J，et al. R-fluoxetine increases melanin synthesis through a 5-HT1A/2A receptor and p38 MAPK signaling pathways[J]. Int J Mol Sci， 2018， 20(1):80.
     [16]Xia SY， Lin RT， Jin LT，et al. Prevention of dietary-fat-fueled ketogenesis attenuates BRAF V600E tumor growth[J]. Cell Metab， 2017， 25(2):358-373.
     [17]Campillos M， Kuhn M， Gavin AC， et al. Drug target identification using side-effect similarity[J]. Science， 2008， 321(5886):263-266 .
     [18]Kuhn M， Letunic I， Jensen LJ， et al. The SIDER database of drugs and side effects[J]. Nucleic Acids Res， 2016， 44(D1):D1075-1079.
     [19]Rocca MS，Vignoli A，Tenori L，et al. Evaluation of serum/urine genomic and metabolomic profiles to improve the adherence to sildenafil therapy in patients with erectile dysfunction[J]. Front Pharmacol， 2020， 11:602369.
     [20]Suchonwanit P， Srisuwanwattana P， Chalermroj N， et al. A randomized， double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia[J]. J Eur Acad Dermatol Venereol， 2018， 32(12):2257-2263.
     [21]Liu J， Li Z， Yan K， et al. Pharmacokinetics and safety of dapoxetine hydrochloride in healthy Chinese men：Impact of dose and high-fat meal[J]. Clin Pharmacol Drug Dev， 2021， 10(10):1216-1224.
     [22]Liu S， Wang Z， Tian X， et al. Corrigendum：predicting the effects of CYP2C19 and carboxylesterases on vicagrel， a novel P2Y12 antagonist， by physiologically based pharmacokinetic/pharmacodynamic modeling approach[J]. Front Pharmacol， 2021， 12:668861.
     [23]Zhang Y， Zhu X， Zhan Y， et al. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel， a novel thienopyridine P2Y(12) inhibitor[J]. Br J Clin Pharmacol， 2020， 86(9):1860-1874.
     [24]Zhang R， Sun X， Li Y， et al. The efficacy and safety of sacubitril/valsartan in heart failure patients:a review[J]. J Cardiovasc Pharmacol Ther， 2022， 27:10742484211058681.
     [25]Zhang T， Lin T， Wang Y， et al. Estimated stroke-free survival of folic acid therapy for hypertensive adults：projection based on the CSPPT[J]. Hypertension， 2020， 75(2):339-346.
     [26]Liu WM， Strauss SJ， Chaplin T， et al. S-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line[J]. Hematol J， 2004， 5(3):247-254.
     [27]圣和药业.圣和一类新药左奥硝唑及左奥硝唑氯化钠注射液上市.[EB/OL].（2009-10-16）[2022-03-30].http://www.sanhome.com/detail.aspx?id=325.
     [28]Mueller SM， Navarini AA， Goldust M， et al. The short-term effect of levocetirizine on quality of life， stress， and depression in itchy psoriasis patients[J]. Dermatol Ther， 2020， 33(1):e13179.
     [29]Yonetani Y， Iwaki K， Ishii M， et al. A new diuretic that does not reduce renal handling of uric acid in rats， S-8666[J]. Jpn J Pharmacol， 1987， 43(4):399-405.
     [30]Masoudi-Sobhanzadeh Y， Omidi Y， Amanlou M， et al. Drug databases and their contributions to drug repurposing[J]. Genomics， 2020， 112(2):1087-1095.
     [31]Parvathaneni V， Kulkarni NS， Muth A， et al. Drug repurposing：a promising tool to accelerate the drug discovery process[J]. Drug Discov Today， 2019， 24(10):2076-2085.
     [32]Gns HS， Gr S， Murahar M， et al. An update on drug repurposing：re-written saga of the drug′s fate[J]. Biomed Pharmacother， 2019， 110:700-716.
     [33]Nabirotchkin S， Peluffo AE， Rinaudo P， et al. Next-generation drug repurposing using human genetics and network biology[J]. Curr Opin Pharmacol， 2020， 51:78-92.
     [34]Timmons JA， Anighoro A， Brogan RJ， et al. A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease[J]. Elife， 2022， 11:e68832.
     [35]Ragot H， Hovnanian A. Drug repurposing reveals mTOR inhibition as a promising strategy for epidermolysis bullosa simplex[J]. J Invest Dermatol， 2022， 142(2):275-278.
     [36]Chai AWY， Tan AC， Cheong SC. Uncovering drug repurposing candidates for head and neck cancers：insights from systematic pharmacogenomics data analysis[J]. Sci Rep， 2021， 11(1):23933.
     [37]Baker NC， Ekins S， Williams AJ， et al. A bibliometric review of drug repurposing[J]. Drug Discov Today， 2018， 23(3):661-672.
     [38]Aslam B,Khurshid M,Arshad MI,et al. Antibiotic resistance: one health one world outlook[J]. Front Cell Infect Microbiol,2021,11:771510.
     [39]Tassler H. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections[J]. Am J Med， 1993， 94(3A):159S-165S.
     [40]Thakare R， Shukla M， Kaul G， et al. Repurposing disulfiram for treatment of Staphylococcus aureus infections[J]. Int J Antimicrob Agents， 2019， 53(6):709-715.
     [41]Chen F， Di H， Wang Y， et al. Small-molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence[J]. Nat ChemBiol， 2016， 12(3)：174-179.
     [42]Sahoo BM， Ravi K， Sruti J， et al. Drug Repurposing Strategy(DRS)：emerging approach to identify potential therapeutics for treatment of novel coronavirus infection[J]. Front Mol Biosci， 2021， 8:628144.
     [43]Yan L， Cyrill KS， Jang HC. Drug repurposing for COVID-19：approaches， challenges and promising candidates[J]. Pharmacol Ther， 2021， 228:107930.
     [44]Jin Z， Du X， Xu Y， et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors[J]. Nature， 2020， 582(7811):289-293.
     [45]Hoffman RL，Kania RS，Brothers MA，et al．Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19[J]. J Med Chem， 2020， 63(21):12725-12747．
     [46]Owen DR， Allerton CMN， Anderson AS，et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19[J]. Science， 2021， 374(6575):1586-1593.
     [47]王雅君，韩容，岳志华，等. 美国儿童药品上市审批情况分析及其对我国儿童用药保障工作的启示[J].中国药房，2021，32(2):133-138.
     [48]李鸿彬,李认书.对上市中成药再评价制度的回顾与思考[J].中草药,2015,46(2): 293-296.
     [49]Pimentel-Nunes P， Libanio D， Marcos-Pinto R， et al. Management of epithelial precancerous conditions and lesions in the stomach(MAPS II)：European Society of Gastrointestinal Endoscopy(ESGE)， European Helicobacter and Microbiota Study Group(EHMSG)， European Society of Pathology(ESP)， and Sociedade Portuguesa de Endoscopia Digestiva(SPED) guideline update 2019[J]. Endoscopy， 2019 ，51(4):365-388.
     [50]钟丽丹.中成药上市后再评价的现状、挑战与展望[J]. 世界中医药，2017，12(6):1212-1220.
     [51]马爱霞，张籍元，钱焊森，等. 医保支付价背景下药物经济学评价的应用探索[J].中国卫生经济，2018，37(2):74-76.

快速检索引用检索图表检索高级检索